Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning

被引:4
作者
Zhan, Min [1 ]
Chen, Zebin [1 ]
Ding, Changcai [2 ]
Qu, Qiang [3 ]
Wang, Guoqiang [1 ]
Liu, Sixi [4 ]
Wen, Feiqiu [4 ]
机构
[1] Shenzhen Childrens Hosp, Dept Pharm, Shenzhen 518036, Peoples R China
[2] Shenzhen Adv Precis Med CO LTD, Dept Res & Dev, Shenzhen 518000, Peoples R China
[3] Xiangya Hosp Cent South Univ, Dept Pharm, Changsha 410008, Peoples R China
[4] Shenzhen Childrens Hosp, Dept Hematol Oncol, Shenzhen 518036, Peoples R China
关键词
Methotrexate clearance; Pediatric hematological malignancies; Pharmacogenomics; SNP genotyping; Machine learning; ACUTE LYMPHOBLASTIC-LEUKEMIA; PLASMA METHOTREXATE; GENETIC-VARIATIONS; ELIMINATION; PHARMACOKINETICS; POLYMORPHISM; TOXICITY; DRUGS; TACROLIMUS; CHILDREN;
D O I
10.1007/s12185-021-03184-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to establish a predictive model to identify children with hematologic malignancy at high risk for delayed clearance of high-dose methotrexate (HD-MTX) based on machine learning. A total of 205 patients were recruited. Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression. The data was randomly split into a "training cohort" and a "validation cohort". A nomogram for prediction of delayed HD-MTX clearance was constructed using the three variables in the training dataset and validated in the validation dataset. Five machine learning algorithms (cart classification and regression trees, naive Bayes, support vector machine, random forest, C5.0 decision tree) combined with different resampling methods were used for model building with five or three variables. When developed machine learning models were evaluated in the validation dataset, the C5.0 decision tree combined with the synthetic minority oversampling technique (SMOTE) using five variables had the highest area under the receiver operating characteristic curve (AUC 0.807 [95% CI 0.724-0.889]), a better performance than the nomogram (AUC 0.69 [95% CI 0.594-0.787]). The results support potential clinical application of machine learning for patient risk classification.
引用
收藏
页码:483 / 493
页数:11
相关论文
共 48 条
  • [1] The curse(s) of dimensionality
    Altman, Naomi
    Krzywinski, Martin
    [J]. NATURE METHODS, 2018, 15 (06) : 399 - 400
  • [2] CORE: core-based synthetic minority over-sampling and borderline majority under-sampling technique
    Bunkhumpornpat, Chumphol
    Sinapiromsaran, Krung
    [J]. INTERNATIONAL JOURNAL OF DATA MINING AND BIOINFORMATICS, 2015, 12 (01) : 44 - 58
  • [3] Pharmacogenomics of Methotrexate: Current Status and Future Outlook
    Cao, Mengda
    Guo, Miao
    Wu, De-Qin
    Meng, Ling
    [J]. CURRENT DRUG METABOLISM, 2018, 19 (14) : 1182 - 1187
  • [4] Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia
    Csordas, Katalin
    Lautner-Csorba, Orsolya
    Semsei, Agnes F.
    Harnos, Andrea
    Hegyi, Marta
    Erdelyi, Daniel J.
    Eipel, Oliver T.
    Szalai, Csaba
    Kovacs, Gabor T.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (03) : 410 - 420
  • [5] Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia
    Gervasini, Guillermo
    Mota-Zamorano, Sonia
    [J]. CURRENT DRUG METABOLISM, 2019, 20 (04) : 313 - 330
  • [6] The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number
    Gregers, Jannie
    Christensen, Ib Jarle
    Dalhoff, Kim
    Lausen, Birgitte
    Schroeder, Henrik
    Rosthoej, Steen
    Carlsen, Niels
    Schmiegelow, Kjeld
    Peterson, Curt
    [J]. BLOOD, 2010, 115 (23) : 4671 - 4677
  • [7] Hospira, 2011, LAB METH INJ
  • [8] Preventing and Managing Toxicities of High-Dose Methotrexate
    Howard, Scott C.
    McCormick, John
    Pui, Ching-Hon
    Buddington, Randall K.
    Harvey, R. Donald
    [J]. ONCOLOGIST, 2016, 21 (12) : 1471 - 1482
  • [9] Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters
    Hu, Ya-Hui
    Zhou, Lin
    Wang, Shan-Shan
    Jing, Xia
    Guo, Hong-Li
    Sun, Fang
    Zhang, Yong
    Chen, Feng
    Xu, Jing
    Ji, Xing
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (06) : 627 - 634
  • [10] Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities
    Hurkmans, Evelien G. E.
    Klumpers, Marije J.
    Vermeulen, Sita H.
    Hagleitner, Melanie M.
    Flucke, Uta
    Schreuder, H. W. Bart
    Gelderblom, Hans
    Bras, Johannes
    Guchelaar, Henk-Jan
    Coenen, Marieke J. H.
    te Loo, D. Maroeska W. M.
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11